prikaz prve stranice dokumenta Risk Factors for Rivaroxaban-Related Bleeding Events - Possible Role of Pharmacogenetics: Case Series
  Preuzmi
PDF 283.64 KB
Znanstveni rad - Prikaz slučaja
Risk Factors for Rivaroxaban-Related Bleeding Events - Possible Role of Pharmacogenetics: Case Series
Pharmacy, 11 (2023), 1; 29. https://doi.org/10.3390/pharmacy11010029
Šimičević, Livija; Slišković, Ana Marija; Vrkić Kirhmajer, Majda; Ganoci, Lana; Holik, Hrvoje; Palić, Jozefina; Samardžić, Jure; Božina, Tamara

Citirajte ovaj rad

Šimičević, L., Slišković, A. M., Vrkić Kirhmajer, M., Ganoci, L., Holik, H., Palić, J. ... Božina, T. (2023). Risk Factors for Rivaroxaban-Related Bleeding Events - Possible Role of Pharmacogenetics: Case Series. Pharmacy, 11. (1). doi: 10.3390/pharmacy11010029

Šimičević, Livija, et al. "Risk Factors for Rivaroxaban-Related Bleeding Events - Possible Role of Pharmacogenetics: Case Series." Pharmacy, vol. 11, br. 1, 2023. https://doi.org/10.3390/pharmacy11010029

Šimičević, Livija, Ana Marija Slišković, Majda Vrkić Kirhmajer, Lana Ganoci, Hrvoje Holik, Jozefina Palić, Jure Samardžić i Tamara Božina. "Risk Factors for Rivaroxaban-Related Bleeding Events - Possible Role of Pharmacogenetics: Case Series." Pharmacy 11, br. 1 (2023). https://doi.org/10.3390/pharmacy11010029

Šimičević, L., et al. (2023) 'Risk Factors for Rivaroxaban-Related Bleeding Events - Possible Role of Pharmacogenetics: Case Series', Pharmacy, 11(1). doi: 10.3390/pharmacy11010029

Šimičević L, Slišković AM, Vrkić Kirhmajer M, Ganoci L, Holik H, Palić J, i sur.. Risk Factors for Rivaroxaban-Related Bleeding Events - Possible Role of Pharmacogenetics: Case Series. Pharmacy [Internet]. 05.02.2023. [pristupljeno 24.12.2024.];11(1). doi: 10.3390/pharmacy11010029

L. Šimičević, et al., "Risk Factors for Rivaroxaban-Related Bleeding Events - Possible Role of Pharmacogenetics: Case Series", Pharmacy, vol. 11, br. 1, Veljača 2023. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:385266. [Citirano: 24.12.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:105:385266
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)Risk Factors for Rivaroxaban-Related Bleeding Events - Possible Role of Pharmacogenetics: Case Series
AutorLivija Šimičević
AutorAna Marija Slišković
AutorMajda Vrkić Kirhmajer
AutorLana Ganoci
AutorHrvoje Holik
AutorJozefina Palić
AutorJure Samardžić
AutorTamara Božina
Autorova ustanovaSveučilište u Zagrebu
Medicinski fakultet
(KATEDRA ZA INTERNU MEDICINU)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Interna medicina
Sažetak (engleski)
Non-vitamin K antagonist oral anticoagulants' interindividual trough concentration variability affects efficacy and safety, especially in bleeding events. Rivaroxaban is metabolised via CYP3A4/5-, CYP2J2-, and CYP-independent mechanisms and is a substrate of two transporter proteins: ABCB1 (MDR1, P-glycoprotein) and ABCG2 (BCRP; breast-cancer-resistance protein). The polymorphisms of these genes may possibly affect the pharmacokinetics of rivaroxaban and, consequently, its safety profile. Rivaroxaban variability may be associated with age, liver and kidney function, concomitant illness and therapy, and pharmacogenetic predisposition. This case series is the first, to our knowledge, that presents multiple risk factors for rivaroxaban-related bleeding (RRB) including age, renal function, concomitant diseases, concomitant treatment, and pharmacogenetic data. It presents patients with RRB, along with their complete clinical and pharmacogenetic data, as well as an evaluation of possible risk factors for RRB. Thirteen patients were carriers of ABCB1, ABCG2, CYP2J2, and/or CYP3A4/5 gene polymorphisms. Possible drug-drug interactions with increased bleeding risk were identified in nine patients. Six patients had eGFR <60 mL/min/1.73 m2. Our data suggest a possible role of multiple factors and their interactions in predicting RRB; however, they also indicate the need for further comprehensive multidisciplinary research to enable safer use of this product based on a personalised approach.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Prikaz slučaja
Status objaveObjavljen
Vrsta recenzijeRecenziran
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaPharmacy
Brojčani podacivol. 11, br. 1, 29
e-ISSN2226-4787
DOIhttps://doi.org/10.3390/pharmacy11010029
URN:NBNurn:nbn:hr:105:385266
Datum objave publikacije2023-02-05
ProjektŠifra: UIP-2020-02-8189
Naziv (hrvatski): Uloga farmakogenomike u predviđanju nuspojava kardiovaskularnih lijekova
Naziv (engleski): Pharmacogenomics in prediction of cardiovascular drugs adverse reaction
Kratica: PGx-CardioDrug
Voditelj: Tamara Božina
Pravna nadležnost: Hrvatska
Financijer: HRZZ
Linija financiranja: UIP
URL dokumentahttps://www.mdpi.com/2226-4787/11/1/29
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Imenovanje 4.0 međunarodna (CC BY 4.0)
Datum i vrijeme pohrane2024-01-15 08:59:15